Hyaluronic acid-coated solid lipid nanoparticles for targeted delivery of vorinostat to CD44 overexpressing cancer cells.

Hyaluronic acid (HA)-decorated solid lipid nanoparticles (SLNs) were developed for tumor-targeted delivery of vorinostat (VRS), a histone deacetylase inhibitor. HA, a naturally occurring polysaccharide, which specifically binds to the CD44 receptor, was coated on a cationic lipid core through electrostatic interaction. After the optimization process, HA-coated VRS-loaded SLNs (HA-VRS-SLNs) were spherical, core-shell nanoparticles, with small size (∼100 nm), negative charge (∼-9 mV), and narrow size distribution. In vitro release profile of HA-VRS-SLNs showed a typical bi-phasic pattern. In addition, the intracellular uptake of HA-VRS-SLNs was significantly enhanced in CD44 overexpressing cells, A549 and SCC-7 cells, but reduced when HA-VRS-SLNs were incubated with SCC-7 cells pretreated with HA or MCF-7 cells with low over-expressed CD44. Of particular importance, HA-VRS-SLNs were more cytotoxic than the free drug and VRS-SLNs in A549 and SCC-7 cells. In addition, HA shell provided longer blood circulation and reduced VRS clearance rate in rats, resulting in enhanced higher plasma concentration and bioavailability. These results clearly indicated the potential of the HA-functionalized lipid nanoparticle as a nano-sized drug formulation for chemotherapy.

[1]  Ajay Kumar,et al.  Enhanced anticancer potential of encapsulated solid lipid nanoparticles of TPD: a novel triterpenediol from Boswellia serrata. , 2013, Molecular pharmaceutics.

[2]  D. Peer,et al.  Paclitaxel-clusters coated with hyaluronan as selective tumor-targeted nanovectors. , 2010, Biomaterials.

[3]  P. Ho,et al.  Histone deacetylase inhibitors: new hope for rheumatoid arthritis? , 2008, Current pharmaceutical design.

[4]  M. Rouini,et al.  The effective encapsulation of a hydrophobic lipid-insoluble drug in solid lipid nanoparticles using a modified double emulsion solvent evaporation method. , 2013, Colloids and surfaces. B, Biointerfaces.

[5]  D. Fischer,et al.  The physical state of lipid nanoparticles influences their effect on in vitro cell viability. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[6]  Parag Aggarwal,et al.  Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. , 2008, Molecular pharmaceutics.

[7]  S. Vinogradov,et al.  Hyaluronic acid-based nanogel-drug conjugates with enhanced anticancer activity designed for the targeting of CD44-positive and drug-resistant tumors. , 2013, Bioconjugate chemistry.

[8]  C. Yap,et al.  Solubilization of vorinostat by cyclodextrins , 2010, Journal of clinical pharmacy and therapeutics.

[9]  Qing-Wen Zhang,et al.  Curcumin-loaded solid lipid nanoparticles have prolonged in vitro antitumour activity, cellular uptake and improved in vivo bioavailability. , 2013, Colloids and surfaces. B, Biointerfaces.

[10]  Kaisar Raza,et al.  Systematically optimized biocompatible isotretinoin-loaded solid lipid nanoparticles (SLNs) for topical treatment of acne. , 2013, Colloids and surfaces. B, Biointerfaces.

[11]  Han‐Gon Choi,et al.  Chitosan-Based Polyelectrolyte Complexes as Potential Nanoparticulate Carriers: Physicochemical and Biological Characterization , 2013, Pharmaceutical Research.

[12]  Jessica E. Bolden,et al.  Anticancer activities of histone deacetylase inhibitors , 2006, Nature Reviews Drug Discovery.

[13]  T. Taguchi,et al.  [Phase I study]. , 1995, Gan to kagaku ryoho. Cancer & chemotherapy.

[14]  M. Nikkhah,et al.  Actions of the anti-cancer drug suberoylanilide hydroxamic acid (SAHA) on human breast cancer cytoarchitecture in silicon microstructures. , 2010, Biomaterials.

[15]  J. Reinmüller.  Hyaluronic acid. , 2003, Aesthetic surgery journal.

[16]  B. Shin,et al.  Development of Vorinostat-Loaded Solid Lipid Nanoparticles to Enhance Pharmacokinetics and Efficacy against Multidrug-Resistant Cancer Cells , 2014, Pharmaceutical Research.

[17]  B. Sarmento,et al.  Brain targeting effect of camptothecin-loaded solid lipid nanoparticles in rat after intravenous administration. , 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[18]  Qiang Zhang,et al.  Preparation, characterization and pharmacokinetics of Amoitone B-loaded long circulating nanostructured lipid carriers. , 2014, Colloids and surfaces. B, Biointerfaces.

[19]  Han‐Gon Choi,et al.  Formulation and optimization of raloxifene-loaded solid lipid nanoparticles to enhance oral bioavailability. , 2014, Journal of nanoscience and nanotechnology.

[20]  Tianyue Jiang,et al.  Dual-functional liposomes based on pH-responsive cell-penetrating peptide and hyaluronic acid for tumor-targeted anticancer drug delivery. , 2012, Biomaterials.

[21]  Han‐Gon Choi,et al.  Layer-by-layer coated lipid-polymer hybrid nanoparticles designed for use in anticancer drug delivery. , 2014, Carbohydrate polymers.

[22]  Sukhen C Ghosh,et al.  CD44: a validated target for improved delivery of cancer therapeutics , 2012, Expert opinion on therapeutic targets.

[23]  Xinli Liu,et al.  Characterization of CD44-mediated cancer cell uptake and intracellular distribution of hyaluronan-grafted liposomes. , 2011, Molecular pharmaceutics.

[24]  Yun-Xia Li,et al.  Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer. , 2013, Cancer letters.

[25]  J. Hamman.  Chitosan Based Polyelectrolyte Complexes as Potential Carrier Materials in Drug Delivery Systems , 2010, Marine drugs.

[26]  T. Andresen,et al.  Hyaluronic acid immobilized polyacrylamide nanoparticle sensors for CD44 receptor targeting and pH measurement in cells. , 2012, Bioconjugate chemistry.

[27]  J. Karp,et al.  Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .

[28]  L. Schwartz,et al.  Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Chong-Kook Kim,et al.  Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. , 2007, Biomaterials.

[30]  N. Davies,et al.  Vorinostat with sustained exposure and high solubility in poly(ethylene glycol)-b-poly(DL-lactic acid) micelle nanocarriers: characterization and effects on pharmacokinetics in rat serum and urine. , 2012, Journal of pharmaceutical sciences.

[31]  P. Diwan,et al.  Increased brain uptake of docetaxel and ketoconazole loaded folate-grafted solid lipid nanoparticles. , 2013, Nanomedicine : nanotechnology, biology, and medicine.

[32]  Ronald Breslow,et al.  Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug , 2007, Nature Biotechnology.